Anti-Obesity Drugs: Global Strategic Business Report

Global Anti-Obesity Drugs Market to Reach $4.8 Billion by 2030

The global market for Anti-Obesity Drugs estimated at US$2.5 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2022-2030. Prescription Drugs, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the OTC Drugs segment is readjusted to a revised 11.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $750.4 Million, While China is Forecast to Grow at 7.5% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$750.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Select Competitors (Total 23 Featured) -

• Eisai Co. Ltd. (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline Plc
• Novo Nordisk A/S (Denmark)
• Rhythm Pharmaceuticals (US)
• VIVUS Inc. (US)

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year